Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Performance Based
View:
Post by goldtech on May 17, 2024 1:05pm

Performance Based

So this Board wants more option shares as the price goes lower!!!!!! This passive rubber stamp Board does nothing in the way of creating any value for the company whatsoever and only think of themselves. As long as they have the decision making for Promis the Company will continue to be lathargic.
Comment by farmerlucy on May 17, 2024 10:31pm
Promis is not in the hand s of a BOD's, it's the Boston Group. This has been the case ever since Promis got involved with them. Now just a matter ot seeing what they do with it. They  could easily dilute it because of their repeated delays to a more increasing percentage for the Boston  majority shareholders and the Israeli company. Getting to the pont where Cashman and other ...more  
Comment by M101 on May 18, 2024 12:27pm
I agree with Farmer here because the MO seems logical, the company has stopped just short of doing anything which would generate big pharma interest, but 1b will cross that line so Boston Group intends to have as much control as they will ever need just prior to that point. But after that the race is on to run up the price asap so that no new investors gain any significant control before the ...more  
Comment by G1945V on May 18, 2024 5:48pm
What % ownership is held by The Boston Group? The shares outstanding 18.96M SEDI shows a total of 34,233,831 ??? The largest shareholder according to SEDI  is " Interinvest Corporation US " at 10,513,222, and " Interinvest Corporation Canada " at 200,000 G1945V
Comment by M101 on May 19, 2024 12:36am
You should google Hans Black  about that SEDI info, goes back to the Amorfix days. I don't know about the current ownership stats and have assumed it doesn't matter because an arms-length investor group is all that's needed to hold control while avoiding reporting requirements. Also, 19 million shares at $1.88 = 35.7 mil cap= just enough to satisfy Nasdaq rule 5550(b), so that ...more  
Comment by G1945V on May 19, 2024 8:26am
So can I say that Hans Peter Black is allegedly a bit of a shady character? https://www.sec.gov/litigation/litreleases/lr-23713 Do you have any idea why SEDI info shows a common share count of over 34 million shares for ProMis Neurosciences Inc.? I just learned that "Interinvest Corporation Inc." is owned and controlled by Hans Peter Black.  G1945V
Comment by G1945V on May 19, 2024 8:50am
Also, I failed to mention that also, Hans Black is a well-known investor and founder of The Boston Group, a private firm based in Boston Massachusetts. As far as I know, the only time the Boston-based investors came up about ProMis was the US$7M financing on March 22, 2021. Mike Gordon (6.11%) Henry McCance (%?) Jeremy Sclar (4.4%) https://www.promisneurosciences.com/news-media/press-releases ...more  
Comment by M101 on May 19, 2024 10:52am
I'm agnostic as to whether Black actually misled investors and how he may be connected to the current investor groups. I hope others jump in here. The company's disclosures are not going to tell us anything useful about the source of control when it's essentially an old boys club. . 
Comment by garygp on May 21, 2024 2:40pm
So is there another cheap a$$ finacing on the burner to enrich everybody but the poor beaten down longterm shareholders in the not too distant future?  Price is now below $1.88, the point where the Aug. 2023 financing was done.  No volume, no cash on hand and no apparent deals in the future where big pharma could partner and alleviate more dilution, and 1b hopefully on the horizon ...more  
Comment by Gbathat on May 22, 2024 12:04pm
I've mentally prepared myself to buy through the phase 2 financing deals.  As price comes down, I'll take advantage of it.  I know that is not the situation for many, and the dilution and price decreases are brutal.  If I can get in at the same prices as those investing tens and eventually hundreds of millions, I'm going to do just that, so long as PMN continues looking ...more  
Comment by goldtech on May 23, 2024 10:44am
They should wait for good news before doing a cheap financing, but this bunch don't know any better.
Comment by M101 on May 25, 2024 6:53pm
It's past-time for the company to drop some rumour that it's working on an anti-310 mab, a targeted dementia bioweapon fully funded by fauci/CIA/Pfizer immune from public disclosure. That would get the share price moving, unless Fauci gets nailed by congress, but what's the chance of that? 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities